Russia's Biocad launches production in North Africa

29 November 2017

Russian biotech and biosimilars company Biocad is launching production in North Africa. As part of these plans, the company will start manufacturing of anti-cancer drugs at the facilities of the Moroccan pharmaceutical company SothemaLabs, reports The Pharma Letter’s local correspondent.

The range will include biosimilars of drugs such as rituximab and bevacizumab, the active ingredients of Roche’s blockbusters drugs Rituxan/MabThera and Avastin that will be produced on the basis of Russian technology.

The Russian copy version of bevacizumab will be 30% cheaper than the original drug. This, according to Biocad, will help it to become one of the leaders in the Moroccan market of anti-cancer drugs.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK